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recently been described. In a retrospective comparison
study of 189 femoropopliteal bypass grafts, there was a
significantly greater incidence rate of grade II (threatened)
ischemia after occlusion of PTFE than with vein grafts
(78% versus 21%).4 These findings were the same for
above-knee and below-knee PTFE grafts. The investiga-
tors concluded that patients who undergo femoropopliteal
bypass grafting with PTFE are at a greater risk for ischemic
limb complications from graft occlusion than are patients
who receive vein grafts.
The role of antithrombotic therapy for prosthetic
femoropopliteal bypass grafting has been based on studies
that compare patency rates with various antithrombotic
treatment regimens. In the published summary from the
most recent American College of Chest Physicians
Consensus Conference on Antithrombotic Therapy,
antiplatelet therapy is recommended for all prosthetic
femoropopliteal bypass grafting procedures.5 This recom-
mendation is made on the basis of the results of two ran-
domized clinical trials that showed superior patency rates
with antiplatelet therapy.6,7 Anticoagulation therapy (war-
Autogenous saphenous vein is generally accepted as
the preferred graft material for infrainguinal bypass graft-
ing surgery. Although several studies have shown accept-
able patency results with polytetrafluoroethylene (PTFE)
for above-knee femoropopliteal bypass grafting,1-3 the
ischemic consequences of PTFE graft failure have only
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Objective: A recent retrospective study showed that the ischemic consequences of femoropopliteal bypass graft occlusion
were more severe with polytetrafluoroethylene (PTFE) than with vein. This study examines this conclusion and whether
oral anticoagulation therapy reduces the degree of ischemia after occlusion of PTFE and vein femoropopliteal bypass
grafts.
Methods: Four hundred two patients who underwent femoropopliteal bypass grafting (233 PTFE and 169 vein) were
randomized to a postoperative regimen of either warfarin (international normalized ratio, 1.4 to 2.8) and aspirin
(WASA; 325 mg daily) therapy or aspirin alone (ASA) therapy. The grade of acute ischemia at the time of graft occlu-
sion was assessed with the Society of Vascular Surgery recommended reporting standards (I, viable; II, threatened).
Early graft occlusions (<30 days) were excluded.
Results: There were 100 graft occlusions (67 PTFE and 33 vein) during a mean follow-up period of 36 months (PTFE)
and 39 months (vein). Forty-eight patients were randomized to WASA therapy, and 52 were randomized to ASA ther-
apy. The patients were well matched for age, atherosclerotic risk factors, operative indication, and preoperative ankle-
brachial index. Overall, a greater percentage of the PTFE occlusions caused grade II ischemia than did the vein graft
occlusions (48% versus 18%; P = .005). The ankle-brachial index at the time of graft occlusion was significantly lower
in the PTFE grafts than in the vein grafts (0.28 versus 0.45; P = .001). The patients with PTFE who were undergo-
ing WASA therapy at the time of graft occlusion had less grade II ischemia than did those patients who were under-
going ASA therapy (28% versus 55%; P = .057). However, the incidence rate of severe ischemia after graft occlusion
remained greater with PTFE grafts and WASA therapy as compared with all the vein grafts (28% versus 18%). The vein
graft occlusions had the same incidence rate of grade II ischemia with WASA therapy as with ASA therapy (20% versus
17%; P = 1.0).
Conclusion: The ischemic consequences of femoropopliteal bypass graft occlusion are worse with PTFE than with vein.
Treatment with WASA therapy lessens the severity of acute ischemia after the occlusion of PTFE graft as compared with
ASA therapy but not to the degree seen with vein graft occlusion. Occlusion of femoropopliteal vein grafts is seldom
accompanied by severe ischemia and is not improved with WASA therapy. (J Vasc Surg 2002;35:292-8.)
farin in combination with aspirin) is only recommended
for patients who are at high risk for graft failure.8
Although the effect of antithrombotic therapy on graft
patency rates has been studied, little information is avail-
able regarding the effect of anticoagulation therapy on the
ischemic consequences of graft failure. The purpose of this
study is the re-examination of the difference in limb
ischemia that results from vein and PTFE femoropopliteal
bypass graft occlusion and the assessment of whether oral
anticoagulation therapy in addition to antiplatelet therapy
reduces the incidence of severe (grade II) ischemia after
graft occlusion.
METHODS
During a 4-year period from 1991 to 1995, 402
patients underwent elective femoropopliteal bypass graft-
ing as part of the Veteran’s Affairs Cooperative Studies
Program (VA CSP) #362, a prospective, multicenter ran-
domized trial designed for the evaluation of the efficacy of
the addition of oral anticoagulation therapy to the long-
term administration of aspirin in patients who undergo
infrainguinal revascularization. The institutional review
boards of each participating VA medical center approved
the study. The 402 patients for femoropopliteal bypass
grafting were part of a total of 831 patients who under-
went elective lower extremity revascularization as part of
the trial. The primary endpoint of VA CSP #362 was
assisted primary patency. An earlier outcome report for
vein bypass grafts was reported elsewhere.9 In this study,
only failed femoropopliteal bypass grafts are analyzed. The
severity of limb ischemia that occurred at the time of graft
occlusion is the primary endpoint. The effect of antithrom-
botic therapy on this endpoint also is analyzed. Clinical cat-
egories of acute limb ischemia were classified according to
the revised Society for Vascular Surgery and American
Association for Vascular Surgery reporting standards as fol-
lows: I, viable; II, threatened; and III, irreversible.10
All patients who underwent elective axillofemoral,
femoral-femoral, femoral-popliteal, or femoral distal
bypass grafting at 17 Department of VA medical centers
were eligible for the study. Only the femoropopliteal grafts
are included in this study. Exclusion criteria were calci-
fied/noncompressible ankle-brachial index (ABI), an ABI
of more than 0.9 in the recipient limb, known hypercoag-
ulable state, contraindication to warfarin or aspirin ther-
apy, emergency surgery, a less than 1-year life expectancy,
serum creatinine level of more than 2.0 mg/dL, poly-
cythemia (red blood cell count, >7.5 × 106/mm), or a
platelet count of more than 106/mm2.
On the first postoperative day, the patients with patent
bypass grafts were stratified by center and according to
bypass graft material (vein or PTFE). Graft type (vein or
PTFE) was not randomized but was chosen by the sur-
geon, usually on the basis of the availability of good qual-
ity saphenous vein. After stratification, randomization to
warfarin plus aspirin (WASA) therapy or aspirin alone
(ASA) therapy was performed. Warfarin was administered
with a target international normalized ratio (INR) range
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of 1.4 to 2.8, a dose requested by the Food and Drug
Administration. Warfarin therapy was started as soon as
the patient resumed oral intake after surgery. The aspirin
dose was 325 mg/day and was started before surgery.
Because some patients in the WASA therapy group were
no longer undergoing warfarin therapy at the time of graft
occlusion, outcome was determined on the basis of actual
anticoagulation status (efficacy analysis) and on the basis
of the initial randomization (intent to treat). The patients
who were randomized to WASA therapy but who had dis-
continued warfarin therapy were counted in the ASA ther-
apy group because they were still taking aspirin.
The patients were followed after surgery for the status
of their leg circulation with symptomatic complaints, pal-
pation of arterial pulses, and Doppler scan–derived pres-
sure determinations (ABI). These evaluations were
performed on the 1st, 5th, and 10th (when still hospital-
ized) postoperative days and at time of hospital discharge.
After discharge, the patients were followed monthly for
INR measurements and were seen every 3 months for clin-
ical assessment. Warfarin therapy was withdrawn if a major
hemorrhagic event occurred (intracranial bleed, hospital-
ization for bleeding, an operation to control bleeding, or
blood transfusion), if the patient’s primary physician
determined that further warfarin therapy was unsafe, or if
the patient requested to have warfarin therapy withdrawn.
ASA therapy compliance was documented with pill counts
at each postoperative visit.
If bypass graft occlusion was suspected on the basis of
a change in the clinical status of the limb or if the ABI was
no longer 0.15 or more above the preoperative value,
duplex ultrasound scanning or angiography was per-
formed. This study includes only those patients with an
occluded bypass graft. At the time of bypass graft occlu-
sion, the clinical status of the limb was determined with a
review of source documents for symptoms, ABI, and grade
of acute limb ischemia (I, II, or III).10 The grade of
Study schema. Antithrombotic therapy indicates status at time of
occlusion. (The two patients who underwent polytetrafluoroeth-
ylene grafting for whom the degree of ischemia could not be
ascertained are excluded from the figure.) Fem-Pop, Femoral-
popliteal; PTFE, polytetrafluoroethylene; WASA, warfarin and
aspirin therapy; ASA, aspirin only therapy.
ischemia at the time of graft occlusion is the primary end-
point of this study. Patency, limb salvage, and mortality
rates were reported elsewhere.9
Descriptive data are presented with the mean and stan-
dard deviation. The differences in categoric variables are
compared between groups with the χ2 test or the Fisher
exact test as appropriate. The differences in continuous
variables are determined with independent sample t tests.
Statistical analysis was performed with the Software
Package for the Social Sciences (version 7.5 for Windows,
SPSS, Inc, Chicago, Ill). Significance was determined at a
P value of less than .05.
RESULTS
Of the 402 femoropopliteal bypass grafts, there were
100 occlusions during an average follow-up period of 36
months (PTFE) and 39 months (vein). All the patients
were well-matched for age, race, prior myocardial infarc-
tion, hypertension, diabetes, cholesterol level, and preop-
erative ABI in the two graft and antithrombotic therapy
groups (Table I).9 The prevalence of active smoking was
similar in the two graft groups. In the vein group, 63.5% of
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the patients were active smokers. For the PTFE group,
68.1% were smokers. Of the 100 graft occlusions, 67
patients received PTFE grafts and 33 had vein grafts (Fig).
Of the 100 occlusions, 48 were initially randomized to
WASA therapy and 52 to ASA therapy. At the time of graft
occlusion, 29 patients were undergoing WASA therapy and
71 were undergoing ASA therapy. The indication for
surgery was claudication in 29 patients and critical ischemia
in 71 patients. The distribution of indications was not sig-
nificantly different for the vein or PTFE groups (critical
ischemia in 78% of vein grafts and in 68% of PTFE grafts;
P = .35) nor was anticoagulation status (critical ischemia in
69% of the WASA therapy group and in 73% of the ASA
therapy group; P = .81). An above-the-knee distal anasto-
mosis was more frequently performed with PTFE grafts
than with vein grafts (87% versus 14%; P < .001).
Of the 100 graft occlusions, 61 resulted in grade I
ischemia, 36 in grade II ischemia, and 1 (ASA therapy
group) in grade III ischemia. In the remaining two occlu-
sions, the grade of ischemia could not be definitively
determined from a review of the source documents. For
the purpose of comparing groups (vein versus PTFE and
WASA versus ASA), the single case of grade III ischemia
was combined with grade II, because these are the most
threatening forms of ischemia. The single case of grade III
ischemia occurred after the occlusion of a PTFE graft. The
occlusion of PTFE grafts was associated with a signifi-
cantly higher incidence rate of grade II ischemia than was
the occlusion of vein grafts (47.7% versus 18.2%; P = .005;
Table II). A comparison of only above-knee PTFE grafts
with all vein grafts yielded similar results. The occlusion of
above-knee PTFE grafts was associated with a 50% inci-
dence rate of grade II ischemia, which was significantly
Table I. Summary characteristics of patients with vein and polytetrafluoroethylene femoropopliteal bypass grafting
Vein PTFE P value
Age (years) 64 ± 6.9 61.2 ± 8.5 .09
Preoperative ABI 0.34 ± .21 0.42 ± .18 .03
Claudication* 24% 32% .44
Critical ischemia* 76% 68%
Below-knee distal anastomosis 86% 13% <.001
WASA (initial randomization) 55% 49% 0.36
WASA (actual treatment) 30% 28% 1
*Initial surgical indication.
PTFE, Polytetrafluoroethylene; ABI, ankle-brachial index; WASA, warfarin and aspirin therapy.
Table III. Comparison of ischemia grade after occlusion
of polytetrafluoroethylene femoropopliteal bypass grafts:
effect of antithrombotic therapy
WASA ASA
Grade I ischemia 13 (72.2%) 21 (44.7%)
Grade II ischemia 5 (27.8%)* 26 (55.3%)*
*P = .057.
WASA, Warfarin and aspirin therapy; ASA, aspirin alone therapy.
Table II. Comparison of ischemia grade after occlusion of polytetrafluoroethylene and vein femoropopliteal bypass
grafts
Vein PTFE Above-knee PTFE
Grade I ischemia 27 (81.8%) 34 (52.3%) 28 (50%)
Grade II ischemia 6 (18.2%) 31 (47.7%)* 28 (50%)†
*P = .005 versus vein.
†P = .003 versus vein.
PTFE, Polytetrafluoroethylene.
greater than the rate with vein grafts (18.2%; P = .003;
Table II).
Of the 67 PTFE graft occlusions, those patients who
underwent treatment with WASA therapy at the time of
graft occlusion had a lower incidence rate of grade II
ischemia than did those patients who underwent treat-
ment only with ASA therapy (27.8% versus 55.3%; P =
.057; Table III). There was no similar benefit in the vein
bypass graft group. Those vein grafts that were treated
with WASA therapy had the same low incidence rate of
grade II ischemia as those treated with ASA therapy only
(20% versus 17.4%; P = 1.00). The incidence rate of grade
II ischemia that occurred with vein graft occlusion regard-
less of antithrombotic therapy was compared with the
ischemia produced with PTFE graft occlusion with WASA
therapy. The 18.2% incidence rate of grade II ischemia
with vein graft occlusion was less than the 27.8% incidence
rate with PTFE graft and WASA therapy, but this differ-
ence did not achieve statistical significance (P = .49).
For those occluded grafts that were treated with
WASA therapy, the INR level appeared to have no effect
on the grade of ischemia at the time of graft occlusion. Of
the six patients with a low INR (<1.4), two (33%) had
grade II ischemia develop. Of the 11 patients with an INR
of 1.4 or greater, four (36%) had grade II ischemia
develop (P = .66).
In an additional subgroup analysis, a study was per-
formed on the effect of anticoagulation therapy on PTFE
grafts on the basis of operative indication. Only five of the
20 PTFE grafting procedures that were performed for
claudication were with anticoagulation therapy, but none
of these cases had severe (grade II) ischemia at the time of
graft occlusion. Of the 15 PTFE grafting procedures that
were performed for claudication without anticoagulation
therapy at the time of graft occlusion, 10 cases (67%) had
grade II ischemia develop (P = .03). A similar but insignif-
icant difference was seen in the PTFE grafting procedures
performed for critical ischemia. In this setting, five of 13
graft occlusions (38.5%) with WASA therapy had grade II
ischemia develop, whereas grade II ischemia occurred in
16 of 31 PTFE grafts (52%) without anticoagulation ther-
apy (ASA therapy only; P = .52).
When the results were stratified for surgical indication,
the outcome was better with vein graft than with PTFE
graft for patients with claudication and with critical ischemia
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(Table IV). Of the 28 patients with claudication with graft
occlusion, none of the vein graft occlusions resulted in
grade II ischemia, whereas 50% of the PTFE graft occlu-
sions resulted in grade II ischemia (P = .025). For those
patients who underwent bypass grafting for critical
ischemia, graft occlusion caused grade II ischemia in 24% of
the vein grafts and in 48% of the PTFE grafts (P = .073).
The incidence rate of major limb amputation (above-
knee or below-knee) was higher after PTFE graft occlu-
sion than with vein graft (24% versus 12%), but this did
not achieve statistical significance (P = .195). The inci-
dence rate of major limb amputation after the occlusion of
PTFE grafts was not influenced by the anticoagulation sta-
tus. The patients with occluded PTFE grafts who under-
went treatment with WASA therapy required amputation
in 26% as compared with 23% with ASA therapy (P = .76).
The time in days from graft occlusion until major limb
amputation was performed varied considerably and was
not different between vein and PTFE grafts (vein, 17.0 ±
15.1 days; PTFE, 109 ± 211 days; P = .10). With only
early amputations (within 30 days of graft occlusion)
included, there was no difference between vein (12%) and
PTFE grafts (15%; P = .1.00).
The postocclusion ABI measurements showed a simi-
lar pattern that favored vein bypass grafts over PTFE grafts
and WASA therapy over ASA therapy. The postocclusion
ABI was significantly lower in the PTFE graft group than
in the vein bypass graft group (0.28 ± 0.22 versus 0.45 ±
0.20; P < .001). Within the PTFE graft group, the post-
occlusion ABI was lower in the ASA therapy group (0.26
± 0.22 versus 0.34 ± 0.18), but this difference was not sta-
tistically significant (P = .13). Postocclusion ABIs were no
Table V. Anticoagulation therapy status at time of graft
occlusion for all patients initially randomized to warfarin
and aspirin therapy
PTFE Vein
Off warfarin therapy 11 8
INR, <1.4 7 3
INR, 1.4 to 2.8 11 6
INR, >2.8 1 1
Total 30 18
PTFE, Polytetrafluoroethylene; INR, international normalized ratio.
Table IV. Comparison of ischemia grade at time of graft occlusion with initial operative indication (claudication or
critical ischemia)
Indication for bypass grafting Vein PTFE
Claudication Grade I ischemia 8 (100%) 10 (50.0%)
Grade II ischemia 0 (0%)* 10 (50.0%)*
Critical ischemia Grade I ischemia 19 (76.0%) 23 (52.3%)
Grade II ischemia 6 (24.0%)† 21 (47.7 %)†
*P = .025.
†P = .073.
PTFE, Polytetrafluoroethylene.
different in the vein bypass graft group for either
antithrombotic regimen (WASA, 0.45 ± 0.22; ASA, 0.45
± 0.20; P = .96).
On an intent-to-treat basis, there were no significant
differences in grade of ischemia between those patients
who were initially randomized to WASA therapy versus
ASA therapy for either graft group. Of the 33 vein graft
occlusions, there were six that resulted in grade II
ischemia, four (22%) in the WASA therapy group and two
(13%) in the ASA therapy group (P = .67). Of the PTFE
grafts, there was a slightly lower incidence rate of grade II
ischemia in the WASA therapy group as compared with the
ASA therapy group (39.3% versus 47.2%), but this did not
achieve statistical significance (P = .62).
Of the 48 patients with graft occlusion who were ini-
tially randomized to WASA therapy, 19 were no longer
undergoing warfarin therapy at the time of graft occlusion
but they were still undergoing ASA therapy (Table V). Of
the 19 patients who were no longer undergoing warfarin
therapy, 12 discontinued for personal choice, 3 stopped
because of a significant bleeding event, and 3 discontinued
for other reasons. Ten of the 48 had a subtherapeutic INR
(<1.4; Table V).
DISCUSSION
Our results clearly indicate an advantage with the use
of vein grafts as compared with PTFE grafts for
femoropopliteal bypass grafting. The incidence rate of
severe, limb-threatening ischemia (grade II, Society for
Vascular Surgery and American Association for Vascular
Surgery) was significantly lower when vein grafts occluded
as compared with PTFE grafts. The superior results
achieved with vein grafts also were observed in compari-
son with only above-knee PTFE grafts. These results sup-
port our earlier findings from a single center review of 189
femoropopliteal bypass grafts in which graft occlusion
resulted in grade II ischemia more often with PTFE grafts
than with vein grafts (78% versus 21%).4 As was the case in
our earlier study, there were far more patients in this study
who underwent femoropopliteal bypass grafting for criti-
cal ischemia than for claudication only (70% versus 28%).
This factor likely accounted for the worse outcomes with
PTFE femoropopliteal bypass grafting than have generally
been reported with claudication. However, subgroup
analysis results in this study showed inferior results with
PTFE graft as compared with vein graft regardless of oper-
ative indication.
Additional data that favor vein graft over PTFE graft
for above-the-knee femoropopliteal bypass grafting were
reported by Johnson and Lee11 for the VA CSP #141.
This randomized clinical trial showed superior 5-year
patency rates with saphenous vein graft (73%) as com-
pared with PTFE graft (39%) and human umbilical vein
graft (53%). Although the ischemic consequences of
graft occlusion were not specifically reported, the higher
rate of major limb amputation with PTFE graft over vein
graft (12.5% versus 8.4%) supported the overall superi-
ority of vein graft. As in this study, most patients in VA
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CSP #141 had critical ischemia as the initial operative
indication.
The practice of many vascular surgeons is to preferen-
tially use PTFE for above-knee femoropopliteal bypass
grafting. The collective conclusions of this study added to
the conclusions of our previous study do not support the
preferential use of PTFE over vein. Our preference for
vein over PTFE is particularly supported when the opera-
tive indication is critical ischemia because these patients
comprised the majority of both studies.
The advantages of vein over PTFE for femoropopliteal
bypass grafting are less clear when considering only claudi-
cation. AbuRahma, Robison, and Holt3 studied 43 patients
who underwent bilateral above-knee femoropopliteal
bypass grafting for claudication. The patients were random-
ized to saphenous vein in one leg and PTFE in the other. In
this study, the 6-year patency rate and the limb salvage rate
were comparable between the two grafts. It is difficult to
draw comparisons between that study and ours, given that
we had so few cases of claudication. Nonetheless, even for
claudication, the degree of ischemia was better with vein
graft failures than with PTFE graft (Table IV).
Given that graft selection was determined by the sur-
geon and was not randomized, one might ask whether this
is a source of bias. One possibility is that such bias would
favor the vein graft group because some surgeons, in an
effort to avoid a below-knee anastomosis with PTFE graft,
might perform an above-knee anastomosis to a more dis-
eased popliteal segment. We have insufficient data to con-
clude whether such bias existed during the conduct of the
study. On the other hand, one might just as easily see
potential bias favoring PTFE graft if it was used preferen-
tially in less diseased popliteal arteries for which an above-
knee anastomosis was possible, with the relegation of the
use of vein to more diseased popliteal arteries for which
only a below-knee anastomosis could be constructed. In
fact, the statistically significantly lower ABI measurements
in the vein graft group would support this latter con-
tention. We think that this may provide additional credi-
bility to the strength of the conclusions favoring vein graft
over PTFE graft.
The other purpose of this study was the evaluation of
the effect of oral anticoagulant therapy on the degree of
ischemia resulting from bypass graft occlusion. Because
this study showed a superiority of vein graft versus PTFE
graft overall, the question of whether anticoagulation
therapy can improve the status of the limb after PTFE
graft occlusion is important. This importance is especially
true if the addition of warfarin to aspirin therapy for PTFE
grafts results in a similarly benign outcome as observed
with vein grafts. On this issue, our results are mixed. The
addition of warfarin therapy reduced the incidence rate of
severe (grade II) ischemia with PTFE graft occlusion.
However, this reduced incidence rate (27.8%) was still
greater than the 18.2% incidence rate observed with vein
graft occlusion. The subgroup analyses at this level are of
such small groups that we cannot conclude with confi-
dence whether the addition of warfarin to aspirin therapy
for PTFE grafts results in similar outcomes as vein grafts
for femoropopliteal bypass grafts. Even if the addition did
benefit, it is doubtful that this “benefit” would outweigh
the additional expense and risk of warfarin therapy in
patients in whom vein is available for above-knee bypass
grafting. For those patients without the possibility of a
vein bypass graft, warfarin therapy may be beneficial
adjunctive therapy.
The role of antiplatelet therapy in patients who
undergo lower extremity revascularization is well sup-
ported. The recommendations from the 2000 American
College of Chest Physicians Consensus Conference on
Antithrombotic Therapy advocate the use of antiplatelet
therapy for prosthetic and autogenous reconstructions.5
The Antiplatelet Trialists’ Collaboration performed an
overview analysis of the effects of antiplatelet therapy on
arterial graft patency from 11 randomized controlled trials
that contained more than 2000 patients overall.12
Antiplatelet therapy, most often with aspirin, produced a
highly significant reduction in occlusion during a mean fol-
low-up period of 19 months. In a more recent review of
this topic, Tangelder and others13 reported a review of ran-
domized clinical trials of aspirin and anticoagulation ther-
apy in the prevention of graft occlusion and ischemic
events after infrainguinal bypass grafting. Five studies on
aspirin therapy were analyzed. In four studies, the bypass
grafts were prosthetic, and in only one study were vein
grafts used. The weighted relative risk for graft occlusion
with antiplatelet therapy was 0.78 (95% confidence inter-
val, 0.64 to 0.95). The relative risk of graft occlusion sup-
ported antiplatelet therapy in all but one study. The
previously mentioned studies clearly support the benefit of
antiplatelet therapy in patients who undergo femoro-
popliteal bypass grafting, regardless of graft type.
The routine administration of WASA therapy for
PTFE femoropopliteal bypass grafting is not currently rec-
ommended on the basis of a review of the existing litera-
ture.5 An exception to this occurs in the treatment of
patients at high risk for graft failure. Sarac and others8
studied the effect of the combination of warfarin (INR, 2
to 3) and aspirin (325 mg/day) therapy on the patency of
infrainguinal vein grafts at high risk for thrombosis. The
factors that identified the grafts at high risk of thrombosis
included previously failed bypass graft, poor arterial
runoff, and marginal vein graft quality. This single center
randomized clinical trial of 56 patients showed superior 3-
year primary patency rates (78% versus 41%) and limb sal-
vage rates in those patients randomized to WASA therapy.
The effect of oral anticoagulation therapy alone as
compared with ASA therapy after infrainguinal bypass
grafting surgery was evaluated in a recently published mul-
ticenter randomized clinical trial of 2690 patients in The
Netherlands (BOA).14 The patients were randomly
assigned to undergo either oral anticoagulation or aspirin
therapy. At a mean of 21 months follow-up period, there
was no difference in the incidence rate of graft occlusion
in either group. Subgroup analysis results suggested that
oral anticoagulation therapy was of benefit with vein
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grafts, whereas aspirin therapy had better results for pros-
thetic grafts. There are important differences between the
BOA study and our own that make the differences in out-
come with anticoagulation therapy difficult to reconcile.
Prosthetic grafts were used in only 32% of the patients in
the BOA study, and of these grafts, only 56% were PTFE.
Perhaps the most significant differences were a higher tar-
get INR (3.0 to 4.5) in the BOA study, the use of differ-
ent anticoagulants (phenprocoumon or avenocoumarol),
and the fact that the BOA anticoagulant group did not
include aspirin therapy. Although the graft occlusion rates
did not differ in the BOA study between the two groups,
an analysis of degree of ischemia after graft occlusion was
not performed.
Although this study was not designed to address the
mechanisms of limb ischemia after graft occlusion, there are
several possible reasons that could account for the poorer
outcomes with PTFE graft. Tibial artery thromboembolism
as a terminal event during graft occlusion is one potential
mechanism. In our earlier report, we found that tibial
runoff scores had worsened after graft occlusion in 50% of
the PTFE graft failures.5 Whether this was the result of
chronic or acute thromboembolism could not be deter-
mined from that study. A blood-biomaterial interaction
with downstream effects causing accelerated atherogenesis
is another possibility. Another potential mechanism might
relate to collateral circulation. Because PTFE grafts can fail
suddenly and without formation of a graft or anastomotic
stenosis, insufficient collateral formation could render the
limb more vulnerable to severe ischemia.
There are a number of limitations in our study. The
original study design of VA CSP #362 did not include an
assessment of the degree of acute limb ischemia associated
with graft occlusion. In fact, the Society for Vascular
Surgery reporting standards were not published until
1997,10 2 years after final enrollment in VA CSP #362.
This study is a subgroup analysis of VA CSP #362.
Another important limitation relates to the continued use
of warfarin therapy. Of the 48 patients with graft occlu-
sions originally randomized to WASA therapy, 19 patients
were no longer undergoing warfarin therapy at the time of
graft occlusion. Of the 29 patients who were still under-
going warfarin therapy, 10 had a subtherapeutic INR.
Even for those patients in whom the target INR of 1.4 to
2.8 was achieved, one might argue that a higher target
INR (2.0 to 3.0) would have been more appropriate.
Perhaps the greatest limitation of the study was that long-
term, therapeutic warfarin therapy was so difficult to
maintain. Finally, it might be difficult to generalize from
our study to patients with claudication with good runoff.
Even though the subgroup analysis showed better results
with vein graft than with PTFE graft, regardless of opera-
tive indication, only 28% of these cases were performed for
claudication.
An additional limitation of the study is that the bene-
fit of WASA therapy in PTFE grafts did not achieve statis-
tical significance as compared with ASA therapy. Although
the two-fold increased risk of severe limb ischemia without
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warfarin therapy would seem to support the use of antico-
agulation therapy, the absence of a statistically significant
difference (P = .057) casts doubt on the validity of this
conclusion. The 50% relative risk reduction rate in severe
ischemia with WASA therapy as compared with ASA ther-
apy in PTFE graft occlusions would, nonetheless, appear
to be clinically significant if this difference is real. The sub-
group analysis results of the effect of anticoagulation ther-
apy on PTFE grafts on the basis of operative indication
suggest a greater benefit for claudication than for critical
ischemia, but this subgroup analysis analyzed a very small
number of patients (n = 20).
The initial report from VA CSP #362 showed no
improvement in patency with WASA therapy as compared
with ASA therapy in 458 patients who underwent lower
extremity bypass grafting surgery.9 This study extends the
set of observations to include an assessment of the sever-
ity of ischemia resulting from bypass graft occlusion. We
conclude that vein grafts are superior to PTFE grafts for
femoropopliteal bypass grafting, given the markedly
diminished incidence of grade II ischemia that accompa-
nies graft occlusion. Secondly, we conclude that the com-
bination of warfarin plus aspirin therapy appears to protect
against severe ischemia in PTFE grafts when occlusion
occurs, particularly when the operative indication is clau-
dication. We cannot say whether PTFE plus WASA ther-
apy is as good as a vein graft for femoropopliteal bypass
grafting, given the small numbers of patients in this sub-
group analysis. The results do suggest, however, that
femoropopliteal bypass grafts constructed with PTFE
should be treated with WASA therapy. However, the
increased costs and hemorrhagic risks of this therapy lead
to the conclusion that PTFE femoropopliteal bypass grafts
should not be used when saphenous vein is available.
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Dr Peter R. F. Bell (Leicester, United Kingdom). Are there
any differences in the rate of myocardial infarction? As you know,
other studies using warfarin have shown a benefit in the lower rate
of infarction of the heart. Did you find that in your study at all?
Secondly, why do you think there was more ischemia when
the PTFE blocked? I find that hard to understand.
Dr Mark R. Jackson. Well, the first question I really can’t
answer. Those data are part of a separate manuscript and were not
made available for this subgroup analysis.
As far as the mechanism of ischemia, we can’t say definitively,
but I think it’s probably thromboembolism, for the following rea-
sons. In our previous study at our own center, in cases where we
had postocclusion angiograms to look at, half of the patients in
the PTFE group had worsening of their tibial runoff scores after
occlusion of PTFE grafts, while this was seldom observed with
vein grafts. Secondly, anticoagulation was protective in PTFE
graft occlusion. If on the other hand, the mechanism of ischemic
outcome was related to differences in collateral formation or
downstream effects associated with the two grafts, then anticoag-
ulation should not have had much effect.
DISCUSSION
